PMC:7200337 / 107348-107621 JSONTXT

{"project":"2_test","denotations":[{"id":"32505227-18018769-46575459","span":{"begin":222,"end":226},"obj":"18018769"},{"id":"32505227-18824060-46575460","span":{"begin":243,"end":247},"obj":"18824060"},{"id":"32505227-31351922-46575461","span":{"begin":267,"end":271},"obj":"31351922"},{"id":"T97524","span":{"begin":222,"end":226},"obj":"18018769"},{"id":"T59957","span":{"begin":243,"end":247},"obj":"18824060"},{"id":"T65299","span":{"begin":267,"end":271},"obj":"31351922"}],"text":"For SARS-CoV-1 and MERS-CoV, animal studies and phase I clinical trials of potential vaccines targeting the S protein had encouraging results, with evidence of nAb induction and induction of cellular immunity (Lin et al., 2007, Martin et al., 2008, Modjarrad et al., 2019)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T41","span":{"begin":110,"end":117},"obj":"Body_part"}],"attributes":[{"id":"A41","pred":"fma_id","subj":"T41","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"For SARS-CoV-1 and MERS-CoV, animal studies and phase I clinical trials of potential vaccines targeting the S protein had encouraging results, with evidence of nAb induction and induction of cellular immunity (Lin et al., 2007, Martin et al., 2008, Modjarrad et al., 2019)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T613","span":{"begin":4,"end":12},"obj":"Disease"}],"attributes":[{"id":"A613","pred":"mondo_id","subj":"T613","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"For SARS-CoV-1 and MERS-CoV, animal studies and phase I clinical trials of potential vaccines targeting the S protein had encouraging results, with evidence of nAb induction and induction of cellular immunity (Lin et al., 2007, Martin et al., 2008, Modjarrad et al., 2019)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T90","span":{"begin":29,"end":35},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"}],"text":"For SARS-CoV-1 and MERS-CoV, animal studies and phase I clinical trials of potential vaccines targeting the S protein had encouraging results, with evidence of nAb induction and induction of cellular immunity (Lin et al., 2007, Martin et al., 2008, Modjarrad et al., 2019)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T69460","span":{"begin":110,"end":117},"obj":"Chemical"},{"id":"T58496","span":{"begin":210,"end":213},"obj":"Chemical"}],"attributes":[{"id":"A28731","pred":"chebi_id","subj":"T69460","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A87966","pred":"chebi_id","subj":"T58496","obj":"http://purl.obolibrary.org/obo/CHEBI_32386"}],"text":"For SARS-CoV-1 and MERS-CoV, animal studies and phase I clinical trials of potential vaccines targeting the S protein had encouraging results, with evidence of nAb induction and induction of cellular immunity (Lin et al., 2007, Martin et al., 2008, Modjarrad et al., 2019)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3604","span":{"begin":4,"end":12},"obj":"Species"},{"id":"3605","span":{"begin":19,"end":27},"obj":"Species"},{"id":"3609","span":{"begin":160,"end":163},"obj":"Chemical"}],"attributes":[{"id":"A3604","pred":"tao:has_database_id","subj":"3604","obj":"Tax:694009"},{"id":"A3605","pred":"tao:has_database_id","subj":"3605","obj":"Tax:1335626"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"For SARS-CoV-1 and MERS-CoV, animal studies and phase I clinical trials of potential vaccines targeting the S protein had encouraging results, with evidence of nAb induction and induction of cellular immunity (Lin et al., 2007, Martin et al., 2008, Modjarrad et al., 2019)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T639","span":{"begin":0,"end":273},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"For SARS-CoV-1 and MERS-CoV, animal studies and phase I clinical trials of potential vaccines targeting the S protein had encouraging results, with evidence of nAb induction and induction of cellular immunity (Lin et al., 2007, Martin et al., 2008, Modjarrad et al., 2019)."}